Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
Holding PRTA?
Track your performance easily
PRTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.70 - $41.55
Previous Close$12.79
Volume603.04K
Average Volume (3M)544.17K
Market Cap
$688.21M
Enterprise Value$180.41M
Total Cash (Recent Filing)$519.30M
Total Debt (Recent Filing)$11.49M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Feb 13, 2025EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding53,808,732
10 Day Avg. Volume491,582
30 Day Avg. Volume544,170
Standard Deviation0.26
R-Squared0.00028
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.29
Price to Sales (P/S)5.16
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit1.97
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$56.80Price Target Upside350.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Prothena News
PremiumCompany Announcements
Prothena Corporation Reports Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsThe upcoming update on the Phase 1 ascent-2 trial for PRX012 could provide visibility into the timing and content of update results, which might support a potential best-in-class product profile.
Financial PerformanceProthena reported 2Q24 earnings and all pipeline programs remain on track.
Strategic AppointmentsThe company also announced the appointment of Chad Swanson, PhD as the new Chief Development Officer.
Bears Say
Clinical Studies FocusDepartures of chief medical officers of development stage companies historically does place more attention on ongoing clinical studies at those companies.
Leadership ChangeCMO departed to pursue opportunity in large pharma.
Market ExpectationsExpectations have come down significantly following the January updates as well as due to the slow ramp of Biogen’s Leqembi.
---
Ownership Overview
13.43% Insiders
27.16% Mutual Funds
37.11% Other Institutional Investors
13.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $12.70 and its highest was $41.55 in the past 12 months.
What is Prothena’s market cap?
Currently, no data Available
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Feb 13, 2025 which is in 48 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Nov 12, 2024. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.168 by $0.068.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -$1.
How many shares outstanding does Prothena have?
Prothena has 53,808,730 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.168. Following the earnings report the stock price went down -0.749%.
Which hedge fund is a major shareholder of Prothena?
Among the largest hedge funds holding Prothena’s share is PRIMECAP Management Co. It holds Prothena’s shares valued at 594K.
---
Prothena Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$56.80 (350.44% Upside)
$56.80 (350.44% Upside)
Hedge Fund Trend
Decreased
By 1.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.72%
12-Months-Change
Fundamentals
Return on Equity
-22.90%
Trailing 12-Months
Asset Growth
-20.31%
Trailing 12-Months
Company Description
Prothena
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
---
PRTA Company Deck
---
PRTA Earnings Call
Q4 2024
0:00 / 0:00
---
PRTA Stock 12 Month Forecast
Average Price Target
$56.80
▲(350.44% Upside)
Technical Analysis
Axsome Therapeutics
―
ACADIA Pharmaceuticals
―
Allogene Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering PRTA
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
-1.93%
assigned a buy rating 7 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -1.93% per trade.
---